Featured Research

from universities, journals, and other organizations

New Hope For Chemo Holidays For Men With Advanced Prostate Cancer

Date:
February 26, 2008
Source:
Oregon Health & Science University
Summary:
Researchers have found that even men with advanced prostate cancer can take a much-needed safe break, or holiday, from chemotherapy. Prior to this study, it wasn't known whether stopping chemotherapy would lead to treatment resistance.

Oregon Health & Science University Cancer Institute researchers, in a first-of-its-kind study, have found that even men with advanced prostate cancer can take a much-needed safe break, or holiday, from chemotherapy.

Related Articles


The double-blind, randomized study, led by principal investigator Tomasz Beer, M.D., recently was published in the journal Cancer.* Beer is the Grover C. Bagby Endowed Chair for Cancer Research, director of the OHSU Cancer Institute Prostate Cancer Program, and associate professor of medicine (hematology/medical oncology), OHSU School of Medicine.

Beer and his team wanted to know if men with metastatic, androgen-independent prostate cancer cancer that has spread from the prostate and is not affected by the male hormone, androgen could take a break from docetaxel, an intravenous chemotherapy delivery drug that is the gold standard treatment for androgen-independent prostate cancer. Docetaxel works by killing cancer cells and slowing cell growth. However, the drug also can cause side effects, such as hair loss, nausea, loss of appetite and increased chance for infections. Chemo holidays can be a much-needed vacation from these side effects.

Prior to this study, it wasn't known whether stopping chemotherapy would lead to treatment resistance.

"We wanted to see if we could improve the quality of life for these patients by giving them time away from chemotherapy and possibly extend the time their cancer is controlled. Essentially, what we proved is that in selected subjects, chemotherapy holidays are feasible and provided meaningful breaks from treatment," said Beer.

This is the first multi-institutional trial to examine outcomes from intermittent chemotherapy. A total of 250 men participated. Of those, 18 percent entered the intermittent arm of the study. These men previously had responded well to chemotherapy.

The median duration of the first chemo holiday was 18 weeks. On resumption of chemotherapy, it the majority of subjects responded to treatment. Specifically, 45.5 percent of participants responded with a greater than 50 percent reduction in prostate specific antigen (PSA) from their post-holiday baseline; of those, 45.5 percent had stable PSAs for at least 12 weeks; and 9.1 percent developed disease progression. Prostate-specific antigen is a protein produced by the cells of the prostate gland and is present in small quantities in the serum of healthy men, and it often elevates when prostate cancer is present. Most men have less than 4 nanograms. Anything higher can indicate prostate cancer.

The next step, said Beer, is to study the addition of immunotherapy, treating the cancer by working with the immune system, during the chemotherapy holidays.

"Because we know holidays are a good thing, we want to find ways to make them even longer," Beer said. OHSU and Beer have significant financial interest in Novacea, Inc., a company that has a commercial interest in the results of this research and technology. This potential conflict was reviewed and a management plan approved by the OHSU Conflict of Interest in Research Committee and the Integrity Program Oversight Council was implemented.

Other authors include: Christopher Ryan, M.D., Division of Hematology/Medical Oncology OHSU Cancer Institute, OHSU School of Medicine; Peter Venner, M.D., Cross Cancer Institute, Alberta Cancer Board, Alberta, Canada; Daniel Petrylak, M.D., Division of Hematology and Medical Oncology, Columbia Presbyterian Medical Center, New York; Gurkamal Chatta, M.D., Pavillion Hellman Cancer Center, University of Pittsburgh; J. Dean Ruether, M.D., Tom Baker Cancer Centre, Alberta Cancer Board, Calgary, Alberta, Canada; Kim Chi, M.D., Division of Medical Oncology, University of British Columbia, Cancer Agency -- Vancouver Centre, Vancouver, British Columbia, Canada; James Young, M.S., and W. David Henner, M.D., Ph.D., Novacea Inc., San Francisco.

*The study is titled: "Intermittent Chemotherapy in Patients With Metastatic Androgen-Independent Prostate Cancer.


Story Source:

The above story is based on materials provided by Oregon Health & Science University. Note: Materials may be edited for content and length.


Cite This Page:

Oregon Health & Science University. "New Hope For Chemo Holidays For Men With Advanced Prostate Cancer." ScienceDaily. ScienceDaily, 26 February 2008. <www.sciencedaily.com/releases/2008/02/080225122331.htm>.
Oregon Health & Science University. (2008, February 26). New Hope For Chemo Holidays For Men With Advanced Prostate Cancer. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2008/02/080225122331.htm
Oregon Health & Science University. "New Hope For Chemo Holidays For Men With Advanced Prostate Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/02/080225122331.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins